中国医药
(600056)
| 流通市值：134.58亿 | | | 总市值：134.63亿 |
| 流通股本：14.95亿 | | | 总股本：14.96亿 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 16,951,924,948.17 | 8,188,780,055.69 | 35,361,621,734.95 | 25,894,435,068.47 |
| 营业收入 | 16,951,924,948.17 | 8,188,780,055.69 | 35,361,621,734.95 | 25,894,435,068.47 |
| 二、营业总成本 | 16,372,550,315.06 | 7,879,789,178.24 | 34,112,387,650.65 | 24,983,221,781.2 |
| 营业成本 | 15,110,394,079.76 | 7,319,970,471.56 | 31,647,847,213.84 | 23,203,636,876.96 |
| 税金及附加 | 52,904,795.79 | 24,131,082.9 | 103,927,929.4 | 74,542,890.22 |
| 销售费用 | 438,720,393.13 | 198,533,489.95 | 1,014,532,766.54 | 759,476,994.57 |
| 管理费用 | 564,303,974.06 | 273,131,624.27 | 1,077,687,896.07 | 808,421,513.7 |
| 研发费用 | 80,949,445.1 | 34,579,994.99 | 158,375,583.87 | 102,129,979.68 |
| 财务费用 | 125,277,627.22 | 29,442,514.57 | 110,016,260.93 | 35,013,526.07 |
| 其中:利息费用 | 90,628,922.49 | 31,638,233.61 | 197,025,891.51 | 111,295,105.66 |
| 其中:利息收入 | 23,970,178.75 | 21,995,446.48 | 34,826,067.57 | 46,795,986.17 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | - | 0 | -2,210,527.65 | 5,891,042.55 |
| 加:投资收益 | 12,526,577.7 | 7,615,328.46 | -68,010,210.63 | 12,899,531.91 |
| 资产处置收益 | 3,105,152.69 | 1,796,810.37 | 10,529,773.61 | 6,962,420.84 |
| 资产减值损失(新) | -3,912,657.81 | 3,437.5 | -150,703,551.68 | -62,486.49 |
| 信用减值损失(新) | -131,806,869.82 | -10,739,878.14 | -69,529,640.29 | -151,790,370.16 |
| 其他收益 | 18,609,221.69 | 5,073,425.99 | 53,678,276.72 | 38,649,220.27 |
| 四、营业利润 | 477,896,057.56 | 312,740,001.63 | 1,022,988,204.38 | 823,762,646.19 |
| 加:营业外收入 | 12,545,657.76 | 3,731,081.52 | 27,021,333.23 | 10,349,733.82 |
| 减:营业外支出 | 10,103,494.94 | 2,163,292.64 | 50,714,740.99 | 11,664,674.55 |
| 五、利润总额 | 480,338,220.38 | 314,307,790.51 | 999,294,796.62 | 822,447,705.46 |
| 减:所得税费用 | 168,117,872.81 | 77,168,271.98 | 324,658,952.78 | 233,736,960.4 |
| 六、净利润 | 312,220,347.57 | 237,139,518.53 | 674,635,843.84 | 588,710,745.06 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 312,220,347.57 | 237,139,518.53 | 674,635,843.84 | 588,710,745.06 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 249,111,341.87 | 182,197,132.89 | 473,229,055.14 | 454,763,908.45 |
| 少数股东损益 | 63,109,005.7 | 54,942,385.64 | 201,406,788.7 | 133,946,836.61 |
| 扣除非经常损益后的净利润 | 230,650,348.4 | 177,482,096.4 | 376,478,717.77 | 394,415,899.55 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.17 | 0.12 | 0.32 | 0.3 |
| (二)稀释每股收益 | 0.17 | 0.12 | 0.32 | 0.3 |
| 八、其他综合收益 | 573,922.49 | -1,525,891.19 | -8,387,833.07 | 613,986.04 |
| 归属于母公司股东的其他综合收益 | 390,244.06 | -1,525,891.19 | -8,511,106.43 | 613,986.04 |
| 九、综合收益总额 | 312,794,270.06 | 235,613,627.34 | 666,248,010.77 | 589,324,731.1 |
| 归属于母公司股东的综合收益总额 | 249,501,585.93 | 180,671,241.7 | 464,717,948.71 | 455,377,894.49 |
| 归属于少数股东的综合收益总额 | 63,292,684.13 | 54,942,385.64 | 201,530,062.06 | 133,946,836.61 |
| 公告日期 | 2026-08-26 | 2026-04-29 | 2026-04-25 | 2025-10-28 |
| 审计意见(境内) | | | 标准无保留意见 | |